MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-29-2025
Incyte Corporation Revenue 2011-2026 | INCY
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Incyte Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.24 B | 3.7 B | 3.39 B | 2.99 B | 2.67 B | 2.16 B | 1.88 B | 1.54 B | 1.11 B | 754 M | 511 M | 355 M | 297 M | 94.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.24 B | 94.5 M | 1.83 B |
Quarterly Revenue Incyte Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.22 B | 1.05 B | - | 1.14 B | 1.04 B | 881 M | - | 919 M | 955 M | 809 M | - | 823 M | 911 M | 733 M | - | 813 M | 706 M | 605 M | 790 M | 621 M | 688 M | 569 M | 579 M | 552 M | 1.58 B | 498 M | 528 M | 450 M | 522 M | 382 M | 444 M | 382 M | 326 M | 384 M | 326 M | 269 M | 246 M | 263 M | 244 M | 188 M | 163 M | 159 M | 124 M | 198 M | 99.6 M | 89.8 M | 97.1 M | 85.1 M | 102 M | 71.1 M | 114 M | 60.5 M | 86.5 M | 36.2 M | 28.9 M | 16.8 M | 16.8 M | 32 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.58 B | 16.8 M | 463 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K |  USA |
 |
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
18.7 M | $ 2.86 | -4.98 % | $ 221 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.32 | 7.79 % | $ 7.99 B |  Australia |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
463 M | $ 10.75 | -4.78 % | $ 695 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
242 K | $ 1.9 | -4.77 % | $ 485 M | Britain |
 |
Ascendis Pharma A/S
ASND
|
364 M | $ 211.51 | -0.81 % | $ 5 B |  Danmark |
 |
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 0.21 | 3.0 % | $ 457 M |  Israel |
 |
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
5.51 M | - | 3.77 % | $ 22.4 M | USA |
 |
CASI Pharmaceuticals
CASI
|
30.2 M | $ 0.81 | -4.71 % | $ 110 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Catalyst Biosciences
CBIO
|
113 M | $ 11.12 | -6.28 % | $ 732 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
1.5 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
78.6 M | - | -7.31 % | $ 87 M | USA |
 |
Certara
CERT
|
385 M | $ 8.73 | -0.91 % | $ 1.4 B | USA |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
60.3 M | - | -15.15 % | $ 60.3 M | Britain |
 |
bluebird bio
BLUE
|
29.5 M | - | - | $ 546 M | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
482 M | $ 96.21 | 1.06 % | $ 27.2 B | Germany |
 |
Calithera Biosciences
CALA
|
9.75 M | - | -10.95 % | $ 876 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
732 M | $ 26.13 | -2.41 % | $ 1.27 B | USA |
 |
BeiGene, Ltd.
BGNE
|
3.81 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Cellectis S.A.
CLLS
|
41.5 M | $ 4.77 | -1.45 % | $ 116 M |  France |
 |
Anika Therapeutics
ANIK
|
167 M | $ 9.31 | -3.12 % | $ 136 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
54 K | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
675 M | $ 36.68 | 5.4 % | $ 3.79 B | USA |
 |
Celldex Therapeutics
CLDX
|
7.02 M | $ 26.99 | -0.63 % | $ 1.74 M | USA |
 |
Axon Enterprise
AXON
|
2.08 B | $ 561.1 | -1.2 % | $ 42.5 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
66.4 M | $ 2.75 | 5.58 % | $ 17.3 M | USA |
 |
AstraZeneca PLC
AZN
|
54.1 B | $ 91.61 | -0.35 % | $ 96.9 B | Britain |
 |
Checkpoint Therapeutics
CKPT
|
41 K | - | - | $ 169 M | USA |